<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Differentiation therapy using <z:chebi fb="2" ids="26536">retinoic acids</z:chebi> (RAs) or 1alpha25-dihydroxyvitamin D3 (D3) is an attractive alternative to chemotherapy in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, with the exception of RA therapy for <z:hpo ids='HP_0011009'>acute</z:hpo> promyelocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (APL), RAs and D3 are not potent enough at doses that can be tolerated by patients </plain></SENT>
<SENT sid="2" pm="."><plain>We demonstrate that <z:chebi fb="0" ids="34648">clofibric acid</z:chebi> (CA) enhances the response of HL60 cells to <z:hpo ids='HP_0000001'>all</z:hpo>-trans RA and D3 </plain></SENT>
<SENT sid="3" pm="."><plain>Our findings and those of others in the field lead us to suggest that combination therapy using <z:hpo ids='HP_0000001'>all</z:hpo>-trans RA and CA should be considered as potential therapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>